• 1
    Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 168391.
  • 2
    Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford) 2005; 44: 12126.
  • 3
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 4
    Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 47681.
  • 5
    Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26: 14019.
  • 6
    Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 7883.
  • 7
    Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 390212.
  • 8
    Maricq HR, Weinberger AB, LeRoy EC. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. J Rheumatol 1982; 9: 28991.
  • 9
    Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982; 72: 8838.
  • 10
    LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 15736.
  • 11
    Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34: 22305.
  • 12
    Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387400.
  • 13
    Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 108893.
  • 14
    Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41: 95105.
  • 15
    Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma [letter]. Arthritis Rheum 2001; 44: 7356.
  • 16
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 17
    Sterz M, McCloskey D. Management: holistic approach to systemic sclerosis. Nurse's approach. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 38592.
  • 18
    Wigley FM, Hummers L. Management: holistic approach to systemic sclerosis. Physician's approach. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 37184.
  • 19
    Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 163047.
  • 20
    Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 116.
  • 21
    Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195205.
  • 22
    Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007; 26: 126874.
  • 23
    Cutolo M, Matucci CM. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 6635.
  • 24
    Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 3542.
  • 25
    Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 35867.
  • 26
    Coulter C, Canadian Scleroderma Research Group, Scleroderma Clinical Trials Consortium, Hudson M, Steele R, Baron M, et al. The development of updated criteria for systemic sclerosis (SSc) using Delphi technique and cluster and frequency analyses from a large SSc patient database [abstract]. Arthritis Rheum 2009; 60 Suppl: S652.
  • 27
    Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis 1979; 5: 513.